Indivior (NASDAQ:INDV) Sees Strong Trading Volume – Time to Buy?

Indivior PLC (NASDAQ:INDV) shares saw an uptick in trading volume on Thursday . 787,928 shares were traded during trading, an increase of 67% from the previous session’s volume of 471,561 shares.The stock last traded at $9.94 and had previously closed at $9.30.

Analyst Ratings Changes

Several research firms have issued reports on INDV. Craig Hallum dropped their target price on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th. Piper Sandler restated an “overweight” rating and issued a $16.00 price target (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Trading Up 16.3 %

The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -253.44 and a beta of 0.70. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.65 and a current ratio of 0.83. The business has a fifty day moving average of $9.61 and a two-hundred day moving average of $13.19.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The firm had revenue of $307.00 million for the quarter, compared to analyst estimates of $302.25 million. As a group, equities analysts expect that Indivior PLC will post 1.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Indivior

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new position in shares of Indivior during the 2nd quarter worth $188,000. VELA Investment Management LLC purchased a new position in shares of Indivior during the 2nd quarter worth $235,000. XTX Topco Ltd purchased a new position in shares of Indivior during the 2nd quarter worth $249,000. Cubist Systematic Strategies LLC lifted its stake in shares of Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after purchasing an additional 6,121 shares during the period. Finally, Forsta AP Fonden purchased a new position in shares of Indivior during the 1st quarter worth $641,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.